Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
All fact checks
AI analysis

Fact check

“Machines used to preserve organs before transplantation are changing the assumption that older donor hearts are unsuitable, and a related study suggests these devices can rejuvenate donor livers to some extent.”
Mostly supportedConfidence: MODERATE

Reasoning

Normothermic perfusion devices have been shown in FDA data and the PROCEED II trial to enable use of hearts from donors over 55 years with survival rates comparable to standard cold storage, indicating a shift in the view that older hearts are unsuitable. A systematic review, however, notes a modest rise in early graft failure, suggesting the benefit is not uniform. For livers, a primary study demonstrated a ~30% reduction in macro‑steatosis and restored ATP after 6 h perfusion, indicating partial histologic rejuvenation, but a larger randomized trial found no significant improvement in 1‑year graft survival. Reuters reporting underscores that long‑term outcomes remain under investigation. Together, the evidence supports the claim’s core ideas but with notable caveats.

On confidence: Evidence from multiple primary studies and regulatory approval supports the claim, but contradictory findings and limited long‑term outcome data temper certainty.

Important context

The claim combines two related but distinct organ types; heart data show expanded donor age eligibility, while liver data show histologic improvement without clear clinical outcome benefit. Regulatory approval and trial results are primary sources, whereas meta‑analysis and larger trials provide counter‑points.

Evidence

Supporting (3)

Contradicting (2)

Contextual (1)

Limitations

Evidence on long‑term graft survival and functional outcomes after perfusion, especially for livers, is limited. The meta‑analysis on hearts includes heterogeneous studies, and the liver rejuvenation claim is based on short‑term ex‑vivo changes rather than post‑transplant performance.

Last verified:
Sep 26, 2026, 4:52 PM CDT
Pipeline:
0.1.0
Claim type:
Factual

Where this claim appeared

Young organs may not be a fountain of youth for recipients

MIT Technology Review · Jessica Hamzelou